Current and Emerging Uses of Statins in Clinical Therapeutics: A Review
Author(s) -
Jonathan Tokonjay Davies,
Spencer Delfino,
Chad E. Feinberg,
Meghan F. Johnson,
Veronica L. Nappi,
Joshua T. Olinger,
Anthony Schwab,
Hollie I. Swanson
Publication year - 2016
Publication title -
lipid insights
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.293
H-Index - 14
ISSN - 1178-6353
DOI - 10.4137/lpi.s37450
Subject(s) - medicine , statin , drug , adverse effect , disease , intensive care medicine , bioinformatics , pharmacology , biology
Statins, a class of cholesterol-lowering medications that inhibit 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase, are commonly administered to treat atherosclerotic cardiovascular disease. Statin use may expand considerably given its potential for treating an array of cholesterol-independent diseases. However, the lack of conclusive evidence supporting these emerging therapeutic uses of statins brings to the fore a number of unanswered questions including uncertainties regarding patient-to-patient variability in response to statins, the most appropriate statin to be used for the desired effect, and the efficacy of statins in treating cholesterol-independent diseases. In this review, the adverse effects, costs, and drug-drug and drug-food interactions associated with statin use are presented. Furthermore, we discuss the pleiotropic effects associated with statins with regard to the onset and progression of autoimmune and inflammatory diseases, cancer, neurodegenerative disorders, strokes, bacterial infections, and human immunodeficiency virus. Understanding these issues will improve the prognosis of patients who are administered statins and potentially expand our ability to treat a wide variety of diseases.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom